Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Ranbaxy to Market Olmesartan in 6 African Countries
January 11, 2010
- Pricing System Reform to Trigger Industry Reorganization
January 11, 2010
- Aricept's Medicoeconomic Benefits Demonstrated
January 11, 2010
- Bayer to Integrate Intendis in April
January 11, 2010
- Pfizer to Break Away from Dependence on Blockbusters: New President Umeda
January 11, 2010
- Female Doctors Tend to Stay Away from Surgery Dept.: Korosho
January 11, 2010
- Welfide Korea Renamed Mitsubishi Tanabe Pharma Korea
January 11, 2010
- FDA Advisory Committee Votes in Favor of Line Extension for Crestor
January 11, 2010
- Toho to Completely Acquire Asucome in February
January 11, 2010
- Coefficient for Generics Not to Be Introduced This April
January 11, 2010
- FPMAJ, JPMA Welcome New Premium as a Step toward New Pricing System
January 11, 2010
- Substitution with Different Strengths to Be Permitted
January 11, 2010
- Chuikyo to Modify Reform Proposal It OK'd on Dec. 22
January 11, 2010
- Measures to Promote Use of Generics to Save \19 Bil. in FY2010
January 11, 2010
- 5% Interest to Be Added to Refunds
January 11, 2010
- Teva-Kowa to Make Taisho Pharm. Its Own Subsidiary
January 11, 2010
- Change in Gov't Helped Drug Pricing System Reform: Mr Nagano
January 11, 2010
- Majority of Pharmacists Explain about Generics Only If Asked by Patients
January 11, 2010
- A Path Opns to Full-Scale Pricing System Reform: Mr Kinoshita
January 11, 2010
- Kyowa Kirin Licenses AD treatment from Immunas
January 11, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…